

Attorney Docket No.: 10294.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Andersen et al.

Confirmation No: 9551

Serial No.: 10/510,386

Group Art Unit: 1636

Filed: October 4, 2004

Examiner: N. Vogel

For: Improved Bacillus Host Cell

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(d)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee. In accordance with 37 C.F.R. § 1.97(d), Applicants enclose the statement specified in 37 C.F.R. § 1.97(e) and the fee set forth in 37 C.F.R. § 1.17(p).

The required fee, estimated to be \$180, was charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: December 18, 2008

/Michael W. Krenicky, Reg. # 45411/  
Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Attorney Docket No.: 10294.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No: 9551

Serial No.: 10/510,386

Group Art Unit: 1636

Filed: October 4, 2004

Examiner: N. Vogel

For: Improved Bacillus Host Cell

STATEMENT UNDER 37 CFR 1.97(e)(1)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Date: December 18, 2008

/Michael W. Krenicky, Reg. # 45411/  
Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097